S. Korean firm seeks FDA nod to test stem cell drug for osteoarthritis

05/8/2013 | BioSpectrum Asia

South Korea's RNL Bio submitted an investigational new drug application to the FDA for RNL-JointStem, its adipose-based stem cell treatment for osteoarthritis. If the application is approved, the firm could begin midstage trials in the U.S. next quarter. RNL-JointStem has conducted Phase I and II studies approved by Korean regulators.

View Full Article in:

BioSpectrum Asia

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Counsel – Regulatory Affairs
RAI Services Company
Winston Salem, NC
Director of Program Development
AdvaMed
Washington DC, DC
Director of System QA
LifeWatch Services, Inc.
Rosemont, IL
Director of Business Development and Membership
AdvaMed
Washington DC, DC
Director, Corporate Counsel
Regeneron
Tarrytown, NY